BACKGROUND: Based on conventional MRI images, it is difficult to differentiatepseudoprogression from true progressionin GBM patients after standard treatment, which isa critical issue associated with survival. The aim of this study was to evaluate th...
Despite the increasing incidence and high morbidity associated with dementia, a simple, non-invasive, and inexpensive method of screening for dementia is yet to be discovered. This study aimed to examine whether artificial intelligence (AI) could dis...
AMIA ... Annual Symposium proceedings. AMIA Symposium
Jan 25, 2021
IgA nephropathy (IgAN) is common worldwide and has heterogeneous phenotypes. Predicting long-term outcomes is important for clinical decision-making. As right-censored patients become common during the long-term follow-up, either excluding these pati...
The concept of Mild Cognitive Impairment (MCI) is used to describe the early stages of Alzheimer's disease (AD), and identification and treatment before further decline is an important clinical task. We selected longitudinal data from the ADNI databa...
BACKGROUND: Identifying variants that drive tumor progression (driver variants) and distinguishing these from variants that are a byproduct of the uncontrolled cell growth in cancer (passenger variants) is a crucial step for understanding tumorigenes...
Alzheimer's disease is the leading cause of dementia. The long progression period in Alzheimer's disease provides a possibility for patients to get early treatment by having routine screenings. However, current clinical diagnostic imaging tools do no...
MOTIVATION: Recurrent neural networks (RNN) are powerful frameworks to model medical time series records. Recent studies showed improved accuracy of predicting future medical events (e.g., readmission, mortality) by leveraging large amount of high-di...
BACKGROUND: Alzheimer's disease (AD) is the most common type of dementia, typically characterized by memory loss followed by progressive cognitive decline and functional impairment. Many clinical trials of potential therapies for AD have failed, and ...
European journal of cancer (Oxford, England : 1990)
Dec 26, 2020
BACKGROUND: CDK4/6 inhibitors plus endocrine therapies are the current standard of care in the first-line treatment of HR+/HER2-negative metastatic breast cancer, but there are no well-established clinical or molecular predictive factors for patient ...
PURPOSE: Rule-based approaches to determining glaucoma progression from visual fields (VFs) alone are discordant and have tradeoffs. To detect better when glaucoma progression is occurring, we used a longitudinal data set of merged VF and clinical da...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.